Modular Medical (Nasdaq: MODD) Unveils Updated Investor Presentation, Emphasizing Disruptive Business Model and Near-Term Milestones

Over the weekend, Modular Medical, Inc. (Nasdaq: MODD), a San Diego-based innovator in insulin delivery technology, quietly published an updated investor presentation, signaling a new phase in its campaign to transform diabetes care. The release comes on the heels of the company’s recent scientific presentations at the American Diabetes Association’s 85th Scientific Sessions and follows a string of strategic business updates, including board appointments and capital raises.

A Business Model Built for Access and Affordability

The newly published presentation, dated June 2025, draws particular attention to the company’s Business Model on page 16—a slide that encapsulates Modular Medical’s strategy to break through the barriers that have historically limited insulin pump adoption. Unlike legacy competitors whose feature-heavy, high-cost pumps have catered primarily to “superusers,” Modular Medical is targeting the vast, underserved population of “almost-pumpers”: insulin-dependent patients who have not adopted pump therapy due to complexity, cost, or insurance hurdles.

“Our mission is to simplify diabetes management and expand access to the higher quality of care that insulin pumps provide,” the company states in its investor materials.

The business model emphasizes:

• Simplicity and Ease of Use: The FDA-cleared MODD1 patch pump is designed for intuitive operation, minimizing the learning curve for both patients and healthcare providers.

• Affordability: By streamlining manufacturing and leveraging a modular design, Modular Medical aims to offer its pumps at a lower price point, making them accessible to a broader patient base and more attractive to payers.

• Recurring Revenue Streams: The model is built around razor/razor-blade economics, with the pump serving as a platform for ongoing sales of consumables and, in the future, additional drug delivery capabilities.

• Scalability: The platform’s modularity is positioned to support rapid iteration and expansion into adjacent markets, including multi-chamber pumps and combination drug-device therapies.

This approach is particularly timely given that only about 20% of insulin-dependent Americans currently use a pump, despite universal need for daily insulin injections. Modular Medical’s leadership, including CEO Jeb Besser and founder Paul DiPerna (previously of Tandem Diabetes (TNDM)), is betting that a user-friendly, affordable solution can unlock a significant portion of this untapped market.

Near-Term Milestones: A Roadmap to Commercialization

Page 17 of the investor presentation lays out a series of Near-Term Milestones that underscore the company’s operational momentum and strategic clarity. These include:

• Manufacturing validation for commercial MODD1 production (Q3 2025)

  • Cartridge first half of quarter
  • Controller second half of quarter

• ADCES Pivot coming soon introduction (August 7-8, 2025) –  3,000+ diabetes care and education specialists along with other healthcare professionals will be at the Association of Diabetes Care & Education Specialists Conference (ADCES25) in Phoenix, August 8-11, for an inspiring experience packed with cutting-edge education and innovative solutions. 

•  Special 510(k) Pivot submission (September/October 2025)

• Limited commercial use of MODD1 (September/October 2025)

• Pivot commercial launch (Q1 2026)

These milestones are supported by a strengthened balance sheet, following a private placement offering that raised approximately $12 million (announced March 20, 2025), and by the appointment of seasoned industry veterans to the board, including Jeff Goldberg, whose experience spans generic insulin development and drug-device combination products. Certain officers and directors (insiders) of the Company purchased units in the private placement at the same price as other investors.

Furthermore, these milestones highlight Modular Medical’s intent to move rapidly from limited launch to broader commercialization, while simultaneously advancing next-generation products and expanding into international markets. The company’s focus on regulatory submissions and clearances—both in the U.S. and Europe—demonstrates a commitment to rigorous compliance and global scalability. The timeline also underscores the company’s dual-track approach: while the initial MODD1 launch will provide early user feedback, the Pivot version—featuring Modular’s proprietary integrated insulin delivery set—is positioned as the flagship product for national and international rollouts, pending regulatory approvals expected in the first quarter of 2026.

Positioning for Impact in Diabetes Care

Modular Medical’s updated presentation seems to serves as both a roadmap and a call to action for investors and stakeholders. By focusing on simplicity, affordability, and scalability, the company is positioning itself to address a persistent gap in diabetes management—one that has left millions of patients reliant on outdated or suboptimal therapies.

As the company advances toward its near-term milestones, the market will be watching closely to see whether Modular Medical can deliver on its promise to democratize insulin pump therapy and capture a meaningful share of a multi-billion-dollar addressable market and/or become an interesting pipeline filling buyout target for other players in this market. i.e. Medtronic (MDT), Tandem Diabetes Care (TNDM), Beta Bionics (BBNX), Insulet (PODD), Abbott (ABT) & DexCom (DXCM).

Sources: